Impact of Multimodal Perioperative Treatment in Patients with Resected Non-Metastatic Grade 3 Neuroendocrine Neoplasms (NEN G3)

#3080

Introduction: Patients with grade 3 neuroendocrine neoplasm (NEN G3) have a limited prognosis. Even in a non-metastatic stage, the risk of recurrence after surgery is high. Multimodal perioperative treatment, including chemotherapy and/or radiotherapy in an adjuvant or neoadjuvant setting, has improved the prognosis in numerous tumor entities; however, it has not been systematically evaluated in NEN G3 so far. Nevertheless, perioperative chemotherapy is generally recommended in most current treatment guidelines for NEN G3.

Aim(s): To analyze the impact of multimodal perioperative treatment on the prognosis of resected NEN G3 patients.

Materials and methods: Retrospective analysis of all patients in the NEN database of our center with non-metastatic NEN G3 who received surgery of the primary tumor between 03/2011 and 11/2019.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Apostolidis L, Starke H, Bhatti I, Jäger D, Winkler E,

Keywords: NEN G3, neuroendocrine carcinoma, adjuvant, neoadjuvant, surgery,